

... , - , , , ;  
... , , , , ,  
... , ,  
... ,  
-6 -10  
... : , , .  
-10 -6  
... : , , .  
( )  
... ,  
... - - ,  
... , 40% [1, 2 ].  
<140/90  
) [2, 3].  
... ,  
... [2].  
7 (Dutch TIA, PATS, HOPE,  
PROGRESS 3 )  
15,527 ,  
... [3, 4].  
« »

[2, 5].

-1, -6, ( ), B [6].

[4, 7, 8].

TEST Trial, Dutch TIA Trial (2004) [7, 9].

[3, 4].

« » [10, 11].

[12].

44 (23, 21) « », 12 : 16 - , 15 - (63±2,9) . : 18 , 1 , 6 , <45%,

14 ) (54±3,7) 30 (16 )  
 ( ), ( ),  
 ( ).  
 . 1.

I –

	(n=30) [95% ]	III (n=44) [95% ]	
	54 [49-58]	62 [53-68]	>0,05
, %	14 (47)	21 (48)	>0,05
, / <sup>2</sup>	24,3 [23-26]	27,2 [25-29]	>0,05
—	126 [123-132]	157 [153-165]	<0,05
.. . .	76 [73-79]	95 [92-98]	<0,05
, ./ .	77 [72-84]	74 [67-85]	>0,05
, /	2,3 [2,0-2,5]	3,7 [3,3-4,0]	<0,05
	-	13 [7-17]	NA
, I/II/III, %	-	39/32/29	NA
, %	-	5 (11,4)	NA
(I-II NYHA), %	-	4(9)	NA
(M)			
- ; NA - ; - ; -			

( ) - ( . - -  
 . ) [13].  
 IBL ( ). - 1  
 DRG ( ). -4, -6,  
 -10 -  
 « - » ( ).  
 , , .  
 , , .  
 48  
 ( )  
 - 70°  
 .  
 (LF) (HF)  
 «DiaCard-II».

1 - . 25-50 .

[2]. « » 3 3 « »

( 140/90 . . , - ( ) )

(m), 95% (M) ( ) . 2\_ -

StatPlus 2009.

p<0,05.

’ . 2) . ,

- 1, -6 - -10 .

: 12 (27%) 3 ,

« » , 5 ,

62%. ( . 2) , -6 - 1 ,

-10. - 1 ,

’ . « »

’ .

- ( . 3).

	(n=30) [95% ]	III (n=44) [95% ]	
			1
, . .	126 [123-132]	153 [149-164] <sup>1</sup>	137 [127-143]* <sup>1</sup>
, . .	76 [73-79]	96 [91-97] <sup>1</sup>	87 [83-93]*
, /	77 [72-84]	78 [69-86]	64 [55-68]* <sup>1</sup>
/ ,	154 [146-161]	221 [195-245] <sup>1</sup>	126 [119-163]*
- 1, /	125,9 [73,5- 178,2]	210 [181,3- 240,4] <sup>1</sup>	188 [160,6- 213,3] <sup>1</sup>
-4	0,2 [0,1-0,5]	0,6 [0,3-0,9]	0,4 [0,2-0,8]
-6	1,3 [0,5-2,1]	7,08 [4,9-10,2] <sup>1</sup>	2,7 [1,9-4,4]* <sup>1</sup>
-10	1,8 [0,95-2,6]	1,22 [0,71-1,88]	4,51 [2,0-7,14]* <sup>1</sup>
-	8,7 [2,5-13,0]	10,5 [8,6-12,4]	6,3 [3,8-9,7] *
<sup>1</sup> – p<0,05 ; * – p<0,05 ; - ; - ;			

	(n=44)	
	LF/HF<2,5 (n=19)	LH/HF 2,5 (n=25)
, . .	-7	-15*
, . .	-6	-9
n (%) ,	16 (84)	1 (4)*
, /	-9	-16
, /	-50	-115*
- 1, /	-11	-35*
-4 /	-0,3	-0,1
-6 /	-3,1	-5,7*
-10 /	+2,2	+3,9
- , /	-3,6	-4,5
* – p<0,05 ; 1; - ;		

LF/HF

2 :

LF/HF 2,5,

LF/HF 2,5,

- 1.

LH/HF 2,5

, -6  
 -10.  
 ,  
 , - 1-  
 ,  
 -6 - , -6  
 ,  
 [15].  
 ,  
 [14].  
 ,  
 2-4 [11].  
 ,  
 -1 , 40% ,  
 [10].  
 .  
 ,  
 LF/HF  
 « » ,  
 , ,  
 , « » .  
 1. ,  
 , - 1 -  
 6.  
 2.  
 .  
 , ,

## SUMMARY

### NEUROHUMORAL AND AUTONOMIC REGULATION IN POST-STROKE HYPERTENSIVE PATIENTS TREATED WITH CARVEDILOL

Vizir V. A., Voloshyna I. M.,  
Zaporozhye State Medical University

Article is devoted to evaluating the effect of carvedilol on neurohumoral and autonomic regulation in post-stroke hypertensive patients. We revealed that carvedilol reduced plasma mediators of sympathetic nervous system and provides anti-inflammatory effect by reducing the concentration of IL-6 and IL-10 increasing in the serum. Antihypertensive efficacy of carvedilol is dependent on the initial state autonomic balance in patients with hypertension combined with cerebrovascular disease.

**Key words:** hypertension, cerebral infarction, carvedilol.

1. . . . . , 2004. – 86 .
2. / . . . . . [ ] // III . . . . . , 2007. – . 87.
3. Staessen J. Blood-pressure lowering for the secondary prevention of stroke / J. Staessen, J. G. Wang // Lancet. – 2001. – Vol. 358. – P. 1026–1028.
4. Lindholm L. H. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis / L. H. Lindholm, B. Carlberg, O. Samuelsson // Lancet. – 2005. – Vol. 366. – P. 1545–1553.
5. Inflammation: a link between hypertension and atherosclerosis/ V. Cachofeiro, M. Miana, N. de las Heras [et al.] // Curr. Hypertens. Rev. – 2009. – Vol. 5. – P. 40–48.
6. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation / Inflammation and Atherosclerosis (EUTOPIA) Investigators // Circulation. – 2004. – Vol. 110. – P. 1103–1107.
7. Atenolol in secondary prevention after stroke / S. Eriksson, B. O. Olofsson, P. O. Wester for the TEST Study Group // Cerebrovasc. Dis. – 1995. – Vol. 5. – P. 21–25.
8. Carlberg B. Atenolol in hypertension: is it a wise choice? / B. Carlberg, O. Samuelsson, L. H. Lindholm // Lancet. – 2004. – Vol. 364. – P. 1684–1689.
9. Predictors of major vascular events in patients with a transient ischemic attack or nondisabling stroke / The Dutch TIA Trial Study Group // Stroke. – 1993. – Vol. 24. – P. 527–531.
10. Strosznajder R. P. Effect of carvedilol on neuronal survival and poly(ADP-ribose) polymerase activity in hippocampus after transient forebrain ischemia / R. P. Strosznajder, H. Jesko, J. Dziewulska // Acta Neurobiol. Exp. (Wars). – 2005. – Vol. 65(2). – P. 137–143.
11. The novel beta-blocker carvedilol, provides neuroprotection in transient focal stroke / S.I. Savitz, J. A. Erhardt, J. V. Anthony [et al.] // J. Cereb. Blood Flow Metab. – 2000. – Vol. 20(8). – P. 1197–1204.
12. Remme W. J. Carvedilol Protects Better Against Vascular Events Than Metoprolol in Heart Failure Results From COMET / W. J. Remme, C. Torp-Pedersen, J. G. F. Cleland // J. Am. Coll. Cardiol. – 2007. – Vol. 49. – P. 963–971.
13. / . . . . . – M. : . . . . . , 2000. – 432 .
14. . . . . 2- / . . . . . // . . . . . – 2007. – 10. – С. 31–36.
15. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischemic stroke correlate with brain infarct volume, stroke severity and long-term outcome / C. J. Smith, H. C. Emsley, C. M. Gavin [et al.] // BMC Neurol. – 2004. – Vol. 4. – P. 223–228.

1 2011 .